|Skip left side navigation and go to content||
Translation of Cardiovascular Molecular Imaging
The National Heart, Lung, and Blood Institute convened a Working Group (WG) meeting on September 16-17, 2009, in Bethesda, Maryland to advise NHLBI on the future of translational cardiovascular molecular imaging (CVMI).The WG members included cardiologists, radiologists, imaging scientists, engineers, and basic scientists with an interest in CVMI. The goal of the meeting was to develop recommendations on how NHLBI could promote the translation of CVMI from the research laboratory into clinically-relevant areas such as diagnostics, monitoring of treatment efficacy, and drug development.
The WG first addressed the current state of the art of CVMI, reviewing each of the molecular imaging modalities in current use and assessing their complementary strengths and potential uses. The WG then reviewed the current state of imaging for a broad range of cardiovascular applications, with a focus on areas where CVMI could fill unmet clinical needs in diagnosis and monitoring of cardiovascular disease. Disease areas covered included:
The WG went on to identify areas where CVMI was likely to have an impact. There was consensus that development of molecular imaging probes should be driven by biological questions, placing an emphasis on novel targets with the ultimate goal of translation to clinical applications. Areas identified included:
Next the WG focused on the barriers to translation of CVMI. The costs associated with the movement of imaging probes to large animal models and ultimately with obtaining FDA approval for use in humans were identified as a major barrier. The WG felt strongly that the FDA needed to be involved as a partner in the development and evaluation of new agents and technologies, as well as in their approval and regulation. Leveraging existing facilities and programs at other institutes was viewed as a potential way of developing synergies and reducing costs. Outreach to professional cardiovascular societies such as AHA and ACC through activities such as CVMI symposia at the annual meetings of these societies would provide a mechanism to increase awareness of the potential of CVMI in the cardiovascular community.
The WG will develop a report of the meeting for publication in an appropriate professional cardiovascular journal.
Denis Buxton, PhD, NHLBI, NIH
Simhan Danthi, PhD, NHLBI, NIH
Melissa Antman, PhD, NHLBI, NIH
Working Group Members:
Last updated: December 4, 2009